Home / Industry News

 

This information is being shared as a benefit to our members about news from our industry partners.

Disclaimer: HFSA is providing this content for informational purposes only. HFSA does not endorse or recommend any commercial products, processes, or services shared in this material. The views and opinions of authors expressed in the material do not necessarily state or reflect those of HFSA and may not be used for advertising or product endorsement purposes.

New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)

NEURO-TTR phase 3 open-label extension study showed TEGSEDI® (inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR amyloidosis with polyneuropathy. Greater efficacy…

0 comments

U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease

The U.S. Food and Drug Administration (FDA) has approved VYNDAQEL® (tafamidis meglumine) and VYNDAMAXTM (tafamidis) for use in adults with cardiomyopathy due to transthyretin amyloidosis….

0 comments

23andMe Adds Another Important Condition to Health Communities–A Community page on HCM is part of a collaboration with MyoKardia

Starting today, 23andMe Health + Ancestry Service customers can access a new Health Community page, focused on hypertrophic cardiomyopathy (HCM), the most common form of…

0 comments

Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine

Mavacamten is Being Developed to Treat the Most Common Inherited Form of Heart Disease, Hypertrophic Cardiomyopathy, for which No Targeted Medical Therapies Exist Twelve-week Treatment…

0 comments

Akcea’s hATTR Compass Genetic Testing Videos: Complete Series is Now Live Online

hATTR Compass, a no-cost, confidential genetic testing and counseling service for patients suspected of having or clinically diagnosed with hATTR amyloidosis with polyneuropathy, has released…

0 comments

FDA approves new device for treating moderate to severe chronic heart failure in patients

March 21, 2019 – The U.S. Food and Drug Administration today approved the Optimizer Smart system for treating patients with chronic, moderate-to-severe heart failure who are…

0 comments

MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM

MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM For more information, visit the…

0 comments

BRILINTA’s Phase III THEMIS trial met primary endopoint in patients with established coronary artery disease and type-2 diabetes

AstraZeneca is pleased to share that the Phase III THEMIS trial met its primary endpoint which demonstrated that BRILINTA® (ticagrelor) tablets, taken in conjunction with…

0 comments

Boehringer Ingelheim and Eli Lilly and Company Announce Top-line Results for CAROLINA Study

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) yesterday announced the CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus Glimepiride in patients with Type 2…

0 comments

New Development in Akcea’s hATTR Compass Program

An exciting new resource has just launched from hATTR Compass, a no-cost, confidential genetic testing and counseling service for patients suspected of having or clinically diagnosed…

0 comments
 

Share This